Strategic focus on the development and commercialisation of novel therapeutics and diagnostics for companion animals.
Highly experienced team with extensive expertise in animal health and a track record of developing and commercialising, pharmaceutical products and supported by world class Key Opinion Leaders.
Portfolio of Intellectual Property across our product range.
Our One Health approach to developing treatments that target diseases in companion animals means our research can translate into the human field.
Our research and development model is simple but effective.
We identify diseases in companion animals where there are no approved treatments.
We formulate novel solutions with species specific doses and presentations.
Our translational research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.
The data collected is then used both as clinical data for veterinary patients and preclinical data for human patients.
We prove the safety and efficacy of our products to FDA and EMA requirements.
We harness our extensive animal research to identify synergies in human medicine.
Our research and development model is simple but effective.
We identify diseases in companion animals where there are no approved treatments.
We formulate novel solutions with species specific doses and presentations.
Our translational research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.
The data collected is then used both as clinical data for veterinary patients and preclinical data for human patients.
We prove the safety and efficacy of our products to FDA and EMA requirements.
We harness our extensive animal research to identify synergies in human medicine.
Keep up to date with our latest advancements and news as we continue to develop and commercialise medicines and diagnostics for use in companion animals.
We are delighted to be working with The Ohio State University on an exciting clinical trial
We are excited to support UC Davis and the Morris Animal Foundation in a novel research. Subvalvular aortic stenosis (SAS)
Our CTO Stuart Fitzgerald and Regulatory Affairs Manager Susan Kennedy had a successful trip to the US
